Products
Atosiban is commercially available as a solution for injection and as an infusion concentrate (Tractocile). It has been approved in many countries since 2002. Generic versions were registered in 2018.
Structure and properties
Atosiban (C43H67N11O12S2, Mr = 994.2 g/mol) is a synthetic nonapeptide derived from oxytocin.
Effects
Atosiban (ATC G02CX01) has labor inhibitory properties. It is a competitive antagonist of oxytocin at its receptors in the myometrium. It additionally binds to vasopressin receptors.
Indications
To delay the threat of preterm delivery in pregnant women. Certain criteria must be met for its use to be indicated.
Dosage
According to the SmPC. The drug is administered as an injection followed by an intravenous infusion.
Contraindications
For complete precautions, see the drug label.
Interactions
Atosiban does not interact with CYP450, and clinically relevant drug-drug interactions are not known.
Adverse effects
The most common potential adverse effects in the pregnant woman include nausea, vomiting, flushing, injection site reactions, hyperglycemia, hypotension, rapid pulse, headache, and dizziness.